As announced by manufacturer Eli Lily today:
“Today, Lilly is reducing the list price of insulins by:
“Today, Lilly is reducing the list price of insulins by:
- Cutting the list price of its non-branded insulin, Insulin Lispro Injection 100 units/mL, to $25 a vial. Effective May 1, 2023, it will be the lowest list-priced mealtime insulin available, and less than the price of a Humalog® vial in 1999.
- Cutting the list price of Humalog®(insulin lispro injection) 100 units/mL1, Lilly's most commonly prescribed insulin, and Humulin®(insulin human) injection 100 units/mL2 by 70%, effective in Q4 2023.
- Launching RezvoglarTM (insulin glargine-aglr) injection, a basal insulin that is biosimilar to, and interchangeable with, Lantus®(insulin glargine) injection, for $92per five pack of KwikPens®, a 78% discount to Lantus, effective April 1, 2023.”
